The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Wnt signaling regulates MFSD2A-dependent drug delivery through endothelial transcytosis in glioma
Abstract
Background: Systemic delivery of anti-tumor therapeutic agents to brain tumors is thwarted by the blood-brain barrier (BBB), an organotypic specialization of brain endothelial cells (ECs). A failure of pharmacological compounds to cross BBB is one culprit for the dismal prognosis of glioblastoma (GBM) patients. Identification of novel vascular targets to overcome the challenges posed by the BBB in tumors for GBM treatment is urgently needed. Methods: Temozolomide (TMZ) delivery was investigated in CT2A and PDGFB-driven RCAS/tv-a orthotopic glioma models. Transcriptome analysis was performed on ECs from murine gliomas. Mfsd2a deficient, Cav1 deficient, and Mfsd2a EC-specific inducible mice were developed to study the underlying molecular mechanisms. Results: We demonstrated that inhibiting Wnt signaling by LGK974 could increase TMZ delivery and sensitize glioma to chemotherapy in both murine glioma models. Transcriptome analysis of ECs from murine gliomas revealed that Wnt signaling inhibition enhanced vascular transcytosis as indicated by the upregulation of PLVAP and downregulation of MFSD2A. Mfsd2a deficiency in mice enhances TMZ delivery in tumors, whereas constitutive expression of Mfsd2a in ECs suppresses the enhanced TMZ delivery induced by Wnt pathway inhibition in murine glioma. In addition, Wnt signaling inhibition enhanced caveolin-1 (Cav1)-positive caveolae-mediated transcytosis in tumor ECs. Moreover, Wnt signaling inhibitor or Mfsd2a deficiency fails to enhance TMZ penetration in tumors from Cav1-deficient mice. Conclusions: These results demonstrated that Wnt signaling regulates MFSD2A-dependent TMZ delivery through a caveolae-mediated EC transcytosis pathway. Our findings identify Wnt signaling as a promising therapeutic target to improve drug delivery for GBM treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LGK974 blood–brain barrier (BBB) modulation | Porcupine inhibition; temporary Wnt/beta-catenin blockade; restoration of caveolae-mediated transcytosis | Orthotopic CT2A and RCAS/tv-a glioma | Blood–brain barrier transcytosis brake (MFSD2A-dependent) | Tumor tissue: quantitative PTX (increased by 2.3–2.6 times) | — | [47]”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [47]
In the citing paper
“The reported increase in intratumoral TMZ and paclitaxel levels is presented in Table 2 explicitly as “LGK974 + drug” versus “drug alone with standard systemic dosing (no. LGK974)” to clarify the control condition [47].”
From Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration (2026) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2021 WHO classification of tumors of the central nervous system: a summary
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab106 · Cited by 12,273
Mfsd2a is critical for the formation and function of the blood-brain barrier
Ben-Zvi, A., Lacoste, B., Kur, E., Andreone, B. J., Mayshar, Y., Yan, H., & Gu, C. (2014) · Nature · doi:10.1038/nature13324 · Cited by 1,037
Canonical Wnt Signaling Regulates Organ-Specific Assembly and Differentiation of CNS Vasculature
Stenman, J. M., Rajagopal, J., Carroll, T. J., Ishibashi, M., McMahon, J., & McMahon, A. P. (2008) · Science · doi:10.1126/science.1164594 · Cited by 641
Essential Regulation of CNS Angiogenesis by the Orphan G Protein–Coupled Receptor GPR124
Kuhnert, F., Mancuso, M. R., Shamloo, A., Wang, H.-T., Choksi, V., Florek, M., Su, H., Fruttiger, M., Young, W. L., Heilshorn, S. C., et al. (2010) · Science · doi:10.1126/science.1196554 · Cited by 301
Flagged first, then by citations
Research works printed but not linked: 30
- Ostrom, 2021, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018, Neuro Oncol., 23, iii1, 10.1093/neuonc/noab200 · DOI
- Sarkaria, 2018, Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data, Neuro Oncol, 20, 184, 10.1093/neuonc/nox175 · DOI · Paper page
- Xie, 2021, Key molecular alterations in endothelial cells in human glioblastoma uncovered t, JCI Insight, 6
- de Gooijer, 2018, Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2, Neoplasia, 20, 710, 10.1016/j.neo.2018.05.001 · DOI · Paper page
- Wick, 2016, Current status and future directions of anti-angiogenic therapy for gliomas, Neuro Oncol, 18, 315, 10.1093/neuonc/nov180 · DOI
- Gerstner, 2020, Bevacizumab reduces permeability and concurrent temozolomide delivery in a subset of patients with recurrent glioblastoma, Clin Cancer Res., 26, 206, 10.1158/1078-0432.CCR-19-1739 · DOI
- Arvanitis, 2020, The blood-brain barrier and blood-tumour barrier in brain tumours and metastases, Nat Rev Cancer., 20, 26, 10.1038/s41568-019-0205-x · DOI
- Daneman, 2009, Wnt/beta-catenin signaling is required for CNS, but not non-CNS, angiogenesis, Proc Natl Acad Sci U S A., 106, 641, 10.1073/pnas.0805165106 · DOI · Paper page
- Gastfriend, 2021, Wnt signaling mediates acquisition o, Elife, 10
- Liebner, 2008, Wnt/beta-catenin signaling controls development of the blood-brain barrier, J Cell Biol., 183, 409, 10.1083/jcb.200806024 · DOI · Paper page
- Boye, 2022, Endothelial Unc5B controls blood-brain barrier integrity, Nat Commun., 13, 1169, 10.1038/s41467-022-28785-9 · DOI
- Martin, 2022, Engineered Wnt ligands enable blood-brain barrier repair in neurological disorders, Science., 375, eabm4459, 10.1126/science.abm4459 · DOI
- Chang, 2017, Gpr124 is essential for blood-brain barrier integrity in central nervous system disease, Nat Med., 23, 450, 10.1038/nm.4309 · DOI
- Tran, 2016, Endothelial beta-catenin signaling is required for maintaining adult blood-brain barrier integrity and central nervous system homeostasis, Circulation., 133, 177, 10.1161/CIRCULATIONAHA.115.015982 · DOI · Paper page
- Phoenix, 2016, Medulloblastoma genotype dictates blood brain barrier phenotype, Cancer Cell, 29, 508, 10.1016/j.ccell.2016.03.002 · DOI
- Griveau, 2018, A glial signature and Wnt7 signaling regulate glioma-vascular interactions and tumor microenvironment, Cancer Cell, 33, 874, 10.1016/j.ccell.2018.03.020 · DOI
- Reis, 2012, Endothelial Wnt/beta-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression, J Exp Med., 209, 1611, 10.1084/jem.20111580 · DOI · Paper page
- Zhang, 2021, 1p/19q co-deletion status is associated with distinct tumor-associated macrophage infiltration in IDH mutated lower-grade gliomas, Cell Oncol, 44, 193, 10.1007/s13402-020-00561-1 · DOI
- Chavali, 2020, Wnt-dependent oligodendroglial-endothelial interactions regulate white matter vascularization and attenuate injury, Neuron., 108, 1130, 10.1016/j.neuron.2020.09.033 · DOI
- Wang, 2020, Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier, Sci Adv., 6, eaba7457, 10.1126/sciadv.aba7457 · DOI
- Heimans, 1994, Paclitaxel (Taxol) concentrations in brain tumor tissue, Ann Oncol., 5, 951, 10.1093/oxfordjournals.annonc.a058736 · DOI
- Niu, 2019, Aberrant oligodendroglial-vascular interactions disrupt the blood-brain barrier, triggering CNS inflammation, Nat Neurosci., 22, 709, 10.1038/s41593-019-0369-4 · DOI
- Andreone, 2017, Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis, Neuron., 94, 581, 10.1016/j.neuron.2017.03.043 · DOI · Paper page
- Schubert, 2001, Caveolae-deficient endothelial cells show defects in the uptake and transport of albumin in vivo, J Biol Chem., 276, 48619, 10.1074/jbc.C100613200 · DOI
- Bosma, 2018, The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema, Fluids Barriers CNS, 15, 24, 10.1186/s12987-018-0109-2 · DOI
- Sorets, 2020, Caveolae-mediated transport at the injured blood-brain barrier as an underexplored pathway for central nervous system drug delivery, Curr Opin Chem Eng., 30, 86, 10.1016/j.coche.2020.08.009 · DOI
- Georganaki, 2018, Vascular targeting to increase the efficiency of immune checkpoint blockade in cancer, Front Immunol., 9, 3081, 10.3389/fimmu.2018.03081 · DOI
- Huang, 2020, Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma, Sci Transl Med., 12, 10.1126/scitranslmed.aay7522 · DOI
- Binda, 2017, Wnt5a drives an invasive phenotype in human glioblastoma stem-like cells, Cancer Res., 77, 996, 10.1158/0008-5472.CAN-16-1693 · DOI
- Hu, 2016, Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth, Cell., 167, 1281, 10.1016/j.cell.2016.10.039 · DOI
Cited by
Sorted by citations
Sheng, J., Yuan, W., Zhang, M., Chen, Z., Qi, Y., Zhao, Y., & Zhang, S. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04028-7 · Cited by 35
Metadata
- Authors
- Xie, Y., He, L., Zhang, Y., Huang, H., Yang, F., Chao, M., Cao, H., Wang, J., Li, Y., Zhang, L., Xin, L., Xiao, B., Shi, X., Zhang, X., Tang, J., Uhrbom, L., Dimberg, A., Wang, L., & Zhang, L.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-01-02
- Volume
- 25
- Issue
- 6
- Pages
- 1073-1084
- ISSN
- 1522-8517
- 1523-5866
- Cited by
- 55
- References
- 4
- Language
- en
- Funders
- National Natural Science Foundation of China
- Swedish Foundation for International Cooperation in Research and Higher Education (STINT) Mobility Program (81911530166, 81702489, 82002659, 81870978, 81772661)
- Swedish Cancer Foundation
- Swedish Science Council
- Natural Science Foundation of Shaanxi Province (2021KW-46, 2020JZ-30)
- Natural Science Foundation of Hunan Province (2022JJ50300)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review